Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A0401
- Development stage
- Preclinical
- Lead developer
- Adcendo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
A0401 is an antibody-drug conjugate (ADC) currently in preclinical development by ADCendo ApS for the treatment of undisclosed solid tumors. As an ADC, its mechanism of action involves the targeted delivery of a cytotoxic payload to cancer cells. The antibody component is designed to bind specifically to an antigen overexpressed on the surface of tumor cells. Upon binding, the ADC-antigen complex is internalized, leading to the release of the cytotoxic payload within the cancer cell, which then induces cell death. The specific target antigen, linker technology, and cytotoxic payload for A0401 are currently undisclosed.
Beyond the preview
Go deeper on A0401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A0401.